PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity

Oncogene

Volumn 27, Issue 24, 2008, Pages 3489-3493

  Tschan, M P ^a   Reddy, V A ^b   Ress, A ^a   Arvidsson, G ^a   Fey, M F ^a,c   Torbett, B E ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

p53; p73; PU.1; Transcriptional repression

Indexed keywords

PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR PU 1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; ERYTHROLEUKEMIA; ERYTHROLEUKEMIA CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OLIGOMERIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; HUMANS; IMMUNOPRECIPITATION; NUCLEAR PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

FRIEND MURINE LEUKEMIA VIRUS;

EID: 44449105031     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1211004     Document Type: Article

References (25)

1. Back J, Dierich A, Bronn C, Kastner P, Chan S. (2004). PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood 103: 3615-3623.
2. Behre G, Whitmarsh AJ, Coghlan MP, Hoang T, Carpenter CL, Zhang DE et al. (1999). c-Jun is a JNK-independent coactivator of the PU.1 transcription factor. J Biol Chem 274: 4939-4946.
3. Benard J, Douc-Rasy S, Ahomadegbe JC. (2003). TP53 family members and human cancers. Hum Mutat 21: 182-191.
4. Britschgi C, Rizzi M, Grob TJ, Tschan MP, Hügli B, Reddy VA et al. (2006). Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene 25: 2030-2039.
5. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. (2005). Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448.
6. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M et al. (2000). Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287: 1804-1808.
7. Cory S, Huang DC, Adams JM. (2003). The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607.
8. Goldschneider D, Million K, Meiller A, Haddada H, Puisieux A, Benard J et al. (2005). The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J Cell Sci 118: 1245-1253.
9. Houston IB, Huang KJ, Jennings SR, DeKoter RP. (2007). PU.1 immortalizes hematopoietic progenitors in a GM-CSF-dependent manner. Exp Hematol 35: 374-384.
10. Inoue K, Roussel MF, Sherr CJ. (1999). Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 96: 3993-3998.
11. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S et al. (2005). Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 106: 1590-1600.
12. Jundt F, Kley K, Anagnostopoulos I, Schulze Probsting K, Greiner A, Mathas S et al. (2002). Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 99: 3060-3062.
13. Kelley LL, Hicks GG, Hsieh FF, Prasher JM, Green WF, Miller MD et al. (1998). Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage. Oncogene 17: 1119-1130.
14. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H et al. (1996). Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 15: 5647-5658.
15. Melino G, De Laurenzi V, Vousden KH. (2002). p73: friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615.
16. Miyake N, Brun AC, Magnusson M, Miyake K, Scadden DT, Karlsson S. (2006). HOXB4-induced self-renewal of hematopoietic stem cells is significantly enhanced by p21 deficiency. Stem Cells 24: 653-661.
17. Moll UM, Slade N. (2004). p63 and p73: roles in development and tumor formation. Mol Cancer Res 2: 371-386.
18. Moreau-Gachelin F. (2006). Lessons from models of murine erythroleukemia to acute myeloid leukemia (AML): proof-of-principle of co-operativity in AML. Haematologica 91: 1644-1652.
19. Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G et al. (1996). Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 16: 2453-2463.
20. Munroe DG, Peacock JW, Benchimol S. (1990). Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol Cell Biol 10: 3307-3313.
21. Nutt SL, Metcalf D, D'Amico A, Polli M, Wu L. (2005). Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med 201: 221-231.
22. Pluta A, Nyman U, Joseph B, Robak T, Zhivotovsky B, Smolewski P. (2006). The role of p73 in hematological malignancies. Leukemia 20: 757-766.
23. Prasher JM, Elenitoba-Johnson KS, Kelley LL. (2001). Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia. Oncogene 20: 2946-2955.
24. Rimmele P, Kosmider O, Mayeux P, Moreau-Gachelin F, Guillouf C. (2007). Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation. Blood 109: 3007-3014.
25. Sherr CJ, Weber JD. (2000). The ARF/p53 pathway. Curr Opin Genet Dev 10: 94-99.